Mizue Terai

1.9k total citations
41 papers, 1.3k citations indexed

About

Mizue Terai is a scholar working on Ophthalmology, Immunology and Molecular Biology. According to data from OpenAlex, Mizue Terai has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Ophthalmology, 16 papers in Immunology and 14 papers in Molecular Biology. Recurrent topics in Mizue Terai's work include Ocular Oncology and Treatments (28 papers), Immunotherapy and Immune Responses (15 papers) and Ubiquitin and proteasome pathways (5 papers). Mizue Terai is often cited by papers focused on Ocular Oncology and Treatments (28 papers), Immunotherapy and Immune Responses (15 papers) and Ubiquitin and proteasome pathways (5 papers). Mizue Terai collaborates with scholars based in United States, Japan and South Korea. Mizue Terai's co-authors include Takami Sato, Michael J. Mastrangelo, Yutaka Tamura, Vitali Alexeev, Andrew E. Aplin, Senthamil R. Selvan, Inna Chervoneva, Ken Kageyama, David Berd and David J. Eschelman and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mizue Terai

41 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mizue Terai

Since Specialization

Citations

This map shows the geographic impact of Mizue Terai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mizue Terai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mizue Terai more than expected).

Fields of papers citing papers by Mizue Terai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mizue Terai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mizue Terai. The network helps show where Mizue Terai may publish in the future.

Co-authorship network of co-authors of Mizue Terai

This figure shows the co-authorship network connecting the top 25 collaborators of Mizue Terai. A scholar is included among the top collaborators of Mizue Terai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mizue Terai. Mizue Terai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress 2024 ·Science Signaling ·Vivian Chua, (unknown), Mizue Terai, Ryota Tanaka, (unknown), Timothy J. Purwin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anna Han, Inna Chervoneva, Michael A. Davies, Julio A. Aguirre‐Ghiso, Takami Sato, Andrew E. Aplin	2
2	A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma 2024 ·Scientific Reports ·Masanori Ozaki, Ken Kageyama, Kenjiro Kimura, (unknown), Akira Yamamoto, Ryota Tanaka, (unknown), (unknown), Hideyuki Nishiofuku, (unknown), Naoki Tani, (unknown), Mizue Terai, Takami Sato, Takeaki Ishizawa, Yukio Miki	1
3	Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth 2023 ·Cancers ·Anna Han, Dzmitry Mukha, Vivian Chua, Timothy J. Purwin, Manoela Tiago, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mizue Terai, Philip Wedegaertner, Takami Sato, Solange Landreville, Michael A. Davies, Stefan Kurtenbach, J. William Harbour, Zachary T. Schug, Andrew E. Aplin	5
4	IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression 2022 ·Molecular Cancer Therapeutics ·(unknown), Bao Lam, Mizue Terai, Takahito Sugase, Ryota Tanaka, Eduardo Farias, (unknown), (unknown), (unknown), (unknown), Julio A. Aguirre‐Ghiso, Andrew E. Aplin, Takami Sato, Jeffrey Benovic	3
5	Improved Uveal Melanoma Copy Number Subtypes Including an Ultra–High-Risk Group 2022 ·SHILAP Revista de lepidopterología ·Emilie Lalonde, Kathryn G. Ewens, Jennifer Richards‐Yutz, (unknown), Mizue Terai, Carin F. Gonsalves, Takami Sato, Carol L. Shields, Arupa Ganguly	10
6	Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells 2021 ·Cancer Research ·Koichi Ito, (unknown), (unknown), Neha Bhagwat, (unknown), (unknown), Joseph Rager, Mizue Terai, Takami Sato, Omar Abdel‐Wahab, (unknown), Peggy Scherle, Kris Vaddi	7
7	A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis 2019 ·Radiology ·Carin F. Gonsalves, David J. Eschelman, (unknown), P.R. Anné, Marlana Orloff, Mizue Terai, Anthony N. Hage, Misung Yi, Inna Chervoneva, Takami Sato	37
8	Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma 2018 ·Molecular Cancer Research ·(unknown), Eduardo Farias, (unknown), Timothy J. Purwin, (unknown), Thomas H. Charpentier, Lihong Zhang, Shihua Wu, Mizue Terai, Takami Sato, Gregory G. Tall, Naiming Zhou, Philip Wedegaertner, Andrew E. Aplin, Julio A. Aguirre‐Ghiso, Jeffrey Benovic	69
9	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma 2017 ·Molecular Cancer Therapeutics ·Hanyin Cheng, Vivian Chua, (unknown), Timothy J. Purwin, Mizue Terai, Ken Kageyama, Michael A. Davies, Takami Sato, Andrew E. Aplin	54
10	Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis 2017 ·Journal of Translational Medicine ·Ken Kageyama, Masahiro Ohara, Kazuki Saito, Shinji Ozaki, Mizue Terai, Michael J. Mastrangelo, Paolo Fortina, Andrew E. Aplin, Takami Sato	35
11	Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma 2015 ·Cancer Research ·Hanyin Cheng, Mizue Terai, Ken Kageyama, Shinji Ozaki, Peter A. McCue, Takami Sato, Andrew E. Aplin	53
12	Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization 2015 ·American Journal Of Pathology ·Shinji Ozaki, (unknown), Ken Kageyama, Mizue Terai, Masahiro Ohara, Hanyin Cheng, Tim Manser, Michael J. Mastrangelo, Andrew E. Aplin, Takami Sato	23
13	Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte–Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases 2015 ·Journal of Vascular and Interventional Radiology ·Matías E. Valsecchi, Mizue Terai, David J. Eschelman, Carin F. Gonsalves, Inna Chervoneva, Jerry A. Shields, Carol L. Shields, Akira Yamamoto, Kevin L. Sullivan, (unknown), David Berd, Michael J. Mastrangelo, Takami Sato	59
14	Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells 2015 ·EBioMedicine ·Mizue Terai, Zhaomei Mu, David J. Eschelman, Carin F. Gonsalves, Ken Kageyama, Inna Chervoneva, Marlana Orloff, Ryan Weight, Michael J. Mastrangelo, Massimo Cristofanilli, Takami Sato	33
15	Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine 2011 ·Cancer Immunology Immunotherapy ·Amit Mahipal, Mizue Terai, David Berd, Inna Chervoneva, Kashyap Patel, Michael J. Mastrangelo, Takami Sato	18
16	Interleukin 6 mediates production of interleukin 10 in metastatic melanoma 2011 ·Cancer Immunology Immunotherapy ·Mizue Terai, Masumi Eto, (unknown), David Berd, Michael J. Mastrangelo, Yutaka Tamura, Kenichi Harigaya, Takami Sato	30
17	Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy 2011 ·Immunologic Research ·Takami Sato, Mizue Terai, Yutaka Tamura, Vitali Alexeev, Michael J. Mastrangelo, Senthamil R. Selvan	200
18	Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential 2009 ·Cancer Immunology Immunotherapy ·Mizue Terai, Yutaka Tamura, Vitali Alexeev, Eiko Ohtsuka, David Berd, Michael J. Mastrangelo, Takami Sato	18
19	Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy 2003 ·Cancer Immunology Immunotherapy ·Takami Sato, Mizue Terai, Rie Yasuda, (unknown), David Berd, Michael J. Mastrangelo, (unknown)	9
20	Human Papillomavirus Type 16 Variants and Risk of Cervical Cancer 2001 ·JNCI Journal of the National Cancer Institute ·(unknown), Mark Schiffman, Christian P. Bromley, Sholom Wacholder, Rolando Herrero, Ana Cecilia Rodríguez, M. Concepción Bratti, Mark E. Sherman, (unknown), Qipu Lin, Mizue Terai, Rebecca Bromley, Kenneth H. Buetow, R. Apple, Robert D. Burk	174

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact